Reported 2 days ago
H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM) with a price target of $80, citing the company's promising gene editing pipeline, particularly their base editing therapies. Beam is advancing various programs for genetic diseases, with significant milestones anticipated, positioning it well for future growth in the biotechnology sector.
Source: YAHOO